Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Version 2 2020-03-25, 10:01Version 2 2020-03-25, 10:01
Version 1 2020-03-25, 09:58Version 1 2020-03-25, 09:58
figure
posted on 2020-03-25, 10:01authored byJennie H. Best, Steven C. Vlad, Lenore Tominna, Ibrahim Abbass
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).